Australian Pavilion to Feature Over 40 Biotechnology Innovators

    SAN DIEGO, June 20 /PRNewswire/ -- Growth and Global Outreach is the key
emerging theme from the soon to be released Australian Biotechnology Report
2001, a collaborative study by Ernst & Young, Freehills and the Australian
Government.  The Australian biotechnology sector has experienced significant
growth since 1999 with a total of at least 190 core biotech companies and
450 biotech related firms.  This is a net increase of about 70 core biotech
companies since the publication of the first Australian Biotechnology Report
two years ago.  There are now approximately 60 publicly listed biotech
companies with an increasing number expanding their operations in the US and
Europe.  Revenues generated by Australian biotech companies (both listed and
private) over the last 12 months are estimated to be nearly AUD$1B and there
are over 150 potential products in clinical or field trials.  The report will
be available at the Australian Pavilion at Bio 2001, June 24-27, San Diego.
    Australia will send 300 delegates to Bio 2001, the largest group of
biotechnology representatives to leave Australian shores.  Victorian Premier
Steve Bracks, Queensland Premier Peter Beattie and South Australian Deputy
Premier Rob Kerin will attend the event.
    The Australian Pavilion is a national initiative, and is supported by
Commonwealth and State & Territory agencies:  Austrade, Biotechnology
Australia, Invest Australia, Bio Innovation SA, Business ACT, Department of
Commerce and Trade WA, Department of Innovation and Information Economy QLD,
NSW Department of State and Regional Development, Tasmanian Department of
State Development, Victorian Department of State and Regional Development.
United Airlines is a corporate sponsor.
    More than 40 of Australia's leading biotech innovators will be featured,
including Adelaide University (Luminis Pty Ltd), Advance Consulting &
Evaluation, Alchemia Pty Ltd, AMRAD Corporation Ltd, Aoris Nova Pty Ltd,
Austrade, Australian Institute of Marine Science, Australian Proteome Analysis
Facility, Autogen, Benitec Ltd, Bio Innovation SA, Bio Nova International Pty
Ltd, Bio21 Cluster/University of Melbourne, BioComm International, Bionomics
Ltd, Biospecialties Australia, Biotech Australia Pty Ltd, BresaGen Ltd,
Business Development & Attraction - ACT Chief Minister's Department, Chemicon
Australia, Clinical Network Services Pty Ltd, CSIRO, Government of Western
Australia-Department of Commerce & Trade, G2 Therapies Ltd/Garvan Institute,
Griffith University, GroPep Limited, Mimotopes Pty Ltd, Monash University, NSW
Department of State & Regional Development, Ozgene Pty Ltd, Peptech Ltd,
ProBio Inc, Queensland Department of State Development, Queensland University
of Technology, Research School of Biological Sciences-Australian National
University, South Australian Research and Development Institute (SARDI),
Tri-Med Australia, UniQuest Pty Ltd, University of Tasmania, Vectogen Ltd,
Victorian Government, Vitapharm Research Pty Ltd, and Western Australian
Biomedical Research Institute.

    For more information about the Australian biotech industry, visit the
online Bio 2001 Press Kit:
http://www.newsdesk.com/vnr/vnrviewco.htm?cli=PRAUSX&show=157196 .

Link to this page: